1. Medtech Insight
  2. >>Geography
  3. >>North America

Entellus Launches New Sinus Treatment Device; Prepares To Release Data From Randomized Study

While launching a new balloon-based device to treat chronic sinusitis, Entellus Medical Inc. revealed it would release details on an important clinical study in July.

While discussing the recent launch of the XprESSLoProfile Multi-Sinus Dilation Tool, Entellus Medical Inc.’s CEO Brian Farley told Medtech Insight that data from the company’s randomized comparative study will be presented in July. Farley says Entellus plans to release the first six months of patient follow-up data from a randomized clinical trial comparing in-office, balloon-based treatment of chronic sinusitis with hospital-based functional endoscopic sinus surgery (FESS).

Although acceptance of balloon-based therapies for sinus treatment is increasing among otolaryngologists, both physicians and insurers have been asking for more clinical data, and specifically for randomized, comparative studies. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

DeepLook AI Imaging Provides A Deeper Look At Dense Breast

DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.

First AI Breast Cancer Prediction Platform Receives FDA Authorization

 
• By Natasha Barrow

Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

More from North America